Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

• Status: Not yet recruiting
• Trial end date: 2026-09-30

Summary

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Celcuity, Inc.
• Treatments: Fulvestrant; Gedatolisib; Palbociclib